NCT05022459View on ClinicalTrials.gov

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis

RecruitingOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

March 31, 2029

Conditions
Hemophilia A
Interventions
DRUG

Emicizumab

Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A

DRUG

FVIII

Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A

Trial Locations (7)

33701

RECRUITING

Johns Hopkins All Children's Hospital, St. Petersburg

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

46260

RECRUITING

Indiana Hemophilia & Thrombosis Center, Indianapolis

48201

RECRUITING

Children's Hospital of Michigan, Detroit

72202

RECRUITING

Arkansas Children's Hospital, Little Rock

94304

RECRUITING

Stanford University, Palo Alto

02215

RECRUITING

Boston Children's Hospital, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Wayne State University

OTHER